Larimar Therapeutics, Inc.
larimartx.comWhat Do They Do?
Develops nomlabofusp, a protein treatment designed to deliver frataxin to people with Friedreich’s ataxia, and uses its delivery platform to pursue treatments for other rare diseases.
10-K for FY2025, filed Mar 19, 2026
How Do They Make Money?
No revenue reported yet.
10-K, filed Mar 5, 2020
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 4, 2026
−$32.8MView ↗
- ▲ +25% (Loss)
- vs −$26.2M in Q2 FY2025
Who Do They Compete With?
Competes with Biogen, Design Therapeutics, Lexeo Therapeutics, Neurocrine Biosciences/Voyager Therapeutics, Solid Biosciences, and PTC Therapeutics
10-K for FY2025, filed Mar 19, 2026The biopharmaceutical industry is characterized by intense and dynamic competition to develop new technologies and proprietary therapies.…View ↗
Loading...
